ClinicalTrials.gg
CompletedNCT04533022Updated May 23, 2025Results posted

Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

A Phase 2 interventional study of C21 in Idiopathic Pulmonary Fibrosis, sponsored by Vicore Pharma AB. Completed at 21 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Vicore Pharma AB · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Idiopathic Pulmonary Fibrosis with a site in India — 1 open to participants now, 5 under way, 3 of them phase 3. Idiopathic Pulmonary Fibrosis · India.

Enrollment
10th of 11
52 · median 274
Started
2020
the only one that year
Phase 2
5 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
1 of 12
Vicore Pharma AB

Among the 12 studies in Idiopathic Pulmonary Fibrosis with a site in India, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 2, and was the 6th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 12 studies in Idiopathic Pulmonary Fibrosis with a site in India is open now. Recruiting first, the newest first:

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Idiopathic Pulmonary Fibrosis with a site in India, or all of them as a file.
02

Study summary

This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written , consistent with ICH-GCP R2 and local laws, obtained before the initiation of any trial related procedure
  2. A diagnosis of IPF within 5 years prior to Visit 1, as per either ATS/ERS/JRS/ATLAT/Fleischner guidelines
  3. Age ≥40 years
  4. Forced vital capacity (FVC) ≥60% predicted at Visit 1 (specifically for UK: FVC ≥80% predicted at Visit 1)
  5. Forced expiratory volume in the first sec ()/FVC ratio ≥0.7 prebronchodilator at Visit 1
  6. Oxygen saturation (SpO2) >85% by pulse oximetry while breathing ambient air at rest at Visit 1
  7. High-resolution computed tomography (HRCT) within 36 months prior to Visit 1 with central reading demonstrating either a or b, and c:

    a. A pattern consistent with usual interstitial pneumonitis (UIP) according to ATS/ERS/JRS/ALAT or Fleischner guidelines i. UIP ii. Probable UIP or b. A pattern indeterminate for UIP according to either ATS/ERS/JRS/ALAT or Fleischner guidelines and a historical consistent with IPF c. Extent of fibrosis > extent of emphysema

  8. Fully vaccinated against COVID-19 prior to screening (Visit 1). Subjects are considered fully vaccinated for COVID-19 ≥14 days after they have received vaccination dose(s) according to local label

Exclusion criteria

Exclusion Criteria:

  1. Previous use of antifibrotic treatment for an interstitial lung disease (e.g. nintedanib or pirfenidone) for > 6 months
  2. Smoking (including e-cigarettes) within 6 months prior to Visit 1
  3. (BMI) >35 or \<18
  4. IPF exacerbation within 3 months prior to Visit 1:

    • Acute worsening or development of dyspnoea typically \<1 month duration
    • Computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia pattern (if no previous computed tomography is available, the qualifier "new" can be dropped)
    • Deterioration not fully explained by cardiac failure or fluid overload
  5. Concurrent serious medical condition with special attention to cardiac or ophthalmic conditions (e.g. to cataract surgery) which in the opinion of the investigator makes the subject inappropriate for this trial
  6. within the past 5 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I
  7. Treatment with any of the medications listed below within 4 weeks prior to Visit 1:

    • Cytochrome p450 (CYP) 3A4 inducers (e.g. rifampicin, phenytoin, St. John's Wort)
    • inhibitors (e.g. clarithromycin, ketoconazole, nefazodone, itraconazole, ritonavir)
    • Medicines that are substrates of CYP1A2, CYP3A4 or CYP2C9 with a narrow therapeutic range
    • Experimental drugs
    • Any systemic therapies other than:
    • Inhaled which can be used throughout the trial period provided the dose is kept stable
    • Corticosteroids for the treatment of acute exacerbations
    • The continuation of stable doses of ≤15 mg daily doses of prednisolone
  8. Treatment with any of the medications listed below within 2 weeks prior to Visit 1:

    • Proton pump inhibitors (PPI's) more than once daily
    • Histamine H2 receptor antagonists (H2RA's)
    • Sulphasalazine and rosuvastatin
    • High dose breast cancer resistance protein sensitive substrates (other than sulphasalazine or rosuvastatin)
  9. Any of the following findings at Visit 1:

    • Prolonged (QT interval with Fridericia's correction) (>450 ms), cardiac arrhythmias or any abnormalities in the resting , as judged by the Investigator
    • Positive results for surface antigen (HBsAg), virus antibody (HCVAb) or 1+2 antigen/antibody (HIV 1+2 Ag/Ab)
    • Positive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin)
  10. Inability to generate lung function data at Visit 1 meeting the minimum standards of the ATS/ERS 2005 guideline, as determined by central review
  11. Clinically significant abnormal laboratory value at Visit 1 indicating a potential risk for the subject if enrolled in the trial as evaluated by the investigator
  12. Pregnant or breast-feeding female subjects
  13. Female subjects of not willing to use methods
  14. Male subjects not willing to use contraceptive methods
  15. Subjects not willing to adhere to dietary restrictions during the trial period
  16. Participation in any other interventional trial during the trial period
  17. Subjects known or suspected of not being able to comply with this trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
  18. Discontinuation or change of previous antifibrotic treatment (e.g. nintedanib or pirfenidone) due to disease progression
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    C21

    C21 100 mg BID (twice daily)

    Drug: C21

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events Occurring Over the Trial Period

    Number of participants with adverse events occurring over the trial period incl. number of participants with any TEAE, serious TEAEs, TEAEs leading to withdrawal from trial, TEAEs leading to discontinuation of treatment, treatment-related TEAEs leading to discontinuation of treatment, TEAEs leading to death, and serious treatment-related TEAEs. Adverse events were recorded from signing of informed consent until end of trial. Nature and frequency of adverse events are presented in details in the adverse events section.

    Time frame: Trial period of 36 weeks

Secondary outcomes

  1. Change From Baseline in Forced Vital Capacity (Non-imputed Data)

    Mean changes in forced vital capacity (FVC) (mL) from baseline to week 12, week 24, and week 36 were calculated

    Time frame: 12, 24, and 36 weeks

  2. Change From Baseline in Forced Vital Capacity (Imputed Data)

    Mean changes in forced vital capacity (FVC) (mL) from baseline to week 12, week 24, and week 36 were calculated

    Time frame: 12, 24, and 36 weeks

  3. Rate of Forced Vital Capacity Decline Over Time, FAS

    Model-based mean (90% CI) FVC changes over 12, 24, and 36 weeks were normalized to change over 24 weeks. A piece-wise linear regression model with knots at weeks 6 and 24 and unstructured covariance matrix was fitted to change from baseline data. Knot selection was performed by visual inspection. The model based change over 12, 24, and 36 weeks was normalized to represent a change over 24 weeks. Rate of decline was computed as y(t) - y(0) = t\*Beta1 + max(0, t-6)\*Beta2 + max(0,t-24)\*Beta3, adjusted to show the decline per 24 weeks, where y is the value at the respective week and Beta is the model coefficient. No imputation of data was conducted.

    Time frame: 12, 24, and 36 weeks

  4. Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Day 1

    The plasma concentration of C21 (ng/mL) was calculated in a subset of subjects at specified timepoints post-dose.

    Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose on Day 1

  5. Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 12

    The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 12 weeks of dosing.

    Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Week 12

  6. Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 24

    The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 24 weeks of dosing.

    Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Week 24

  7. Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 36

    The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 36 weeks of dosing.

    Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Week 36

  8. Cmax in a Sub-set of Subjects

    The maximal plasma concentration (Cmax (ng/ml)) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing

    Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36

  9. Tmax in a Sub-set of Subjects

    The time for the maximal plasma concentration (Tmax (h)) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing

    Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36

  10. AUClast in a Sub-set of Subjects

    Area under the plasma concentration time curve to the last quantified concentration (AUClast) (h\*ng/mL) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing

    Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36

  11. Accumulation Ratio AUC in a Sub-set of Subjects

    Accumulation ratio AUC was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing

    Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36

07

Results

Posted May 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneC21 100 mg BID
Started52
Completed27
Not completed25
Withdrew: Withdrawal by subject15
Withdrew: Adverse event6
Withdrew: Death1
Withdrew: Fvc decline and fvcpp<60%2
Withdrew: Fvc decline, fvcpp<60% and worsening of respiratory symptoms1

Outcome measures

PrimaryNumber of Participants With Adverse Events Occurring Over the Trial Period

Number of participants with adverse events occurring over the trial period incl. number of participants with any TEAE, serious TEAEs, TEAEs leading to withdrawal from trial, TEAEs leading to discontinuation of treatment, treatment-related TEAEs leading to discontinuation of treatment, TEAEs leading to death, and serious treatment-related TEAEs. Adverse events were recorded from signing of informed consent until end of trial. Nature and frequency of adverse events are presented in details in the adverse events section.

Time frame:
Trial period of 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Occurring Over the Trial Period
ParticipantsC21 100 mg BID, SAS
Total number of subjects with treatment-emergent adverse events (TEAEs)37
Total number of subjects with serious TEAEs5
Total number of subjects with TEAEs leading to withdrawal from study6
Total number of subjects with TEAEs leading to discontinuation of treatment12
Total number of subjects with treatment-related TEAEs leading to discontinuation of treatment3
Total number of subjects with TEAEs leading to death2
Total number of subjects with serious treatment-related TEAEs0
SecondaryChange From Baseline in Forced Vital Capacity (Non-imputed Data)

Mean changes in forced vital capacity (FVC) (mL) from baseline to week 12, week 24, and week 36 were calculated

Time frame:
12, 24, and 36 weeks
Reported as:
Mean · mL
Change From Baseline in Forced Vital Capacity (Non-imputed Data)
mLC21 100 mg BID
Week 12-4.9 (-73.2 to 63.4)
Week 2416.0 (-117.4 to 149.3)
Week 36216.0 (36.9 to 395.1)
SecondaryChange From Baseline in Forced Vital Capacity (Imputed Data)

Mean changes in forced vital capacity (FVC) (mL) from baseline to week 12, week 24, and week 36 were calculated

Time frame:
12, 24, and 36 weeks
Reported as:
Mean · mL
Change From Baseline in Forced Vital Capacity (Imputed Data)
mLC21 100 mg BID
Week 12-57.6 (-123.3 to 8.1)
Week 24-70.3 (-170.5 to 29.9)
Week 369.4 (-115.6 to 134.4)
SecondaryRate of Forced Vital Capacity Decline Over Time, FAS

Model-based mean (90% CI) FVC changes over 12, 24, and 36 weeks were normalized to change over 24 weeks. A piece-wise linear regression model with knots at weeks 6 and 24 and unstructured covariance matrix was fitted to change from baseline data. Knot selection was performed by visual inspection. The model based change over 12, 24, and 36 weeks was normalized to represent a change over 24 weeks. Rate of decline was computed as y(t) - y(0) = t\*Beta1 + max(0, t-6)\*Beta2 + max(0,t-24)\*Beta3, adjusted to show the decline per 24 weeks, where y is the value at the respective week and Beta is the model coefficient. No imputation of data was conducted.

Time frame:
12, 24, and 36 weeks
Reported as:
Mean · mL
Rate of Forced Vital Capacity Decline Over Time, FAS
mLC21 100 mg BID
Week 12-8.2 (-141.9 to 125.5)
Week 2436.4 (-87.1 to 160)
Week 36108.9 (-4.8 to 222.6)
SecondaryPlasma Concentration of C21 Evaluated in a Sub-set of Subjects, Day 1

The plasma concentration of C21 (ng/mL) was calculated in a subset of subjects at specified timepoints post-dose.

Time frame:
Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose on Day 1
Reported as:
Mean · ng/mL
Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Day 1
ng/mLC21 100 mg BID
Prior to dosing5.00 ± 0.00
30 min post dose1622.0 ± 1453.64
1 h post dose1788.11 ± 1112.48
2 h post dose864.46 ± 1062.15
3 h post dose322.19 ± 407.29
4 h post dose282.82 ± 379.31
SecondaryPlasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 12

The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 12 weeks of dosing.

Time frame:
Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Week 12
Reported as:
Mean · ng/mL
Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 12
ng/mLC21 100 mg BID
Prior to dosing27.13 ± 62.58
30 min post dose974.28 ± 1028.90
1 h post dose1044.02 ± 1128.30
2 h post dose794.02 ± 774.34
3 h post dose491.25 ± 820.36
4 h post dose101.50 ± 113.96
SecondaryPlasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 24

The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 24 weeks of dosing.

Time frame:
Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Week 24
Reported as:
Mean · ng/mL
Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 24
ng/mLC21 100 mg BID
Prior to dosing20.14 ± 28.608
30 min post dose615.53 ± 792.908
1 h post dose898.61 ± 779.723
2 h post dose404.80 ± 296.002
3 h post dose151.30 ± 125.292
4 h post dose115.93 ± 151.833
SecondaryPlasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 36

The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 36 weeks of dosing.

Time frame:
Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Week 36
Reported as:
Mean · ng/mL
Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 36
ng/mLC21 100 mg BID
Prior to dosing89.78 ± 176.452
30 min post dose796.29 ± 839.353
1 h post dose713.86 ± 453.540
2 h post dose298.29 ± 299.235
3 h post dose374.16 ± 459.545
4 h post dose348.11 ± 479.786
SecondaryCmax in a Sub-set of Subjects

The maximal plasma concentration (Cmax (ng/ml)) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing

Time frame:
Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36
Reported as:
Geometric mean · ng/mL
Cmax in a Sub-set of Subjects
ng/mLC21 100 mg BID
0 Weeks1852.13 ± 80.1
12 Weeks954.29 ± 127.9
24 Weeks524.79 ± 281.6
36 Weeks961.86 ± 73.3
SecondaryTmax in a Sub-set of Subjects

The time for the maximal plasma concentration (Tmax (h)) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing

Time frame:
Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36
Reported as:
Median · h
Tmax in a Sub-set of Subjects
hC21 100 mg BID
Week 01.00 (0.5 to 4.0)
Week 121.50 (0.5 to 4.0)
Week 241.00 (0.0 to 1.0)
Week 361.00 (0.5 to 4.00)
SecondaryAUClast in a Sub-set of Subjects

Area under the plasma concentration time curve to the last quantified concentration (AUClast) (h\*ng/mL) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing

Time frame:
Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36
Reported as:
Geometric mean · h*ng/mL
AUClast in a Sub-set of Subjects
h*ng/mLC21 100 mg BID
Week 03018.151 ± 60.5
Week 121704.924 ± 126.6
Week 24995.600 ± 213.2
Week 361622.774 ± 49.8
SecondaryAccumulation Ratio AUC in a Sub-set of Subjects

Accumulation ratio AUC was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing

Time frame:
Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36
Reported as:
Geometric mean · Ratio
Accumulation Ratio AUC in a Sub-set of Subjects
RatioC21 100 mg BID
Week 120.84598 ± 120.5
Week 240.45256 ± 328.9
Week 360.73765 ± 67.9

Adverse events

Collected over Throughout the trial from signing of informed consent until the end-of-trial visit, up to 44 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
C21 100 mg BID2/52 (3.8%)5/52 (9.6%)35/52 (67.3%)
Most frequent serious events
Most frequent serious events
EventC21 100 mg BID
Angina pectorisCardiac disorders1/52
Cardiac failureCardiac disorders1/52
COVID-19Infections and infestations1/52
Kidney infectionInfections and infestations1/52
SepsisCardiac disorders1/52
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders1/52
PneumonitisRespiratory, thoracic and mediastinal disorders1/52
Type 2 diabetes mellitusMetabolism and nutrition disorders1/52
Squamous cell carcinoma of the oral cavityNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/52
Most frequent other events
Showing 10 of 23
Most frequent other events
EventC21 100 mg BID
AlopeciaSkin and subcutaneous tissue disorders10/52
RashSkin and subcutaneous tissue disorders4/52
Gastro-oesophageal reflux diseaseGastrointestinal disorders4/52
Blood creatinine increasedInvestigations4/52
CoughRespiratory, thoracic and mediastinal disorders4/52
PyrexiaGeneral disorders4/52
DiarrhoeaGastrointestinal disorders3/52
C-reactive protein increasedInvestigations3/52
Lower respiratory tract infectionInfections and infestations3/52
DyspnoeaRespiratory, thoracic and mediastinal disorders3/52

Baseline characteristics

Age, Continuous
Age, Continuous(Years)C21 100 mg BID, SAS
Mean67.3 ± 9.38
Sex: Female, Male
Sex: Female, Male(Participants)C21 100 mg BID, SAS
Female12
Male40
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)C21 100 mg BID, SAS
Hispanic or Latino0
Not Hispanic or Latino52
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)C21 100 mg BID, SAS
American Indian or Alaska Native0
Asian38
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)C21 100 mg BID, SAS
Ukraine4
United Kingdom7
India38
Russia3
Height
Height(cm)C21 100 mg BID, SAS
Mean161.69 ± 8.723
Weight
Weight(kg)C21 100 mg BID, SAS
Mean64.64 ± 14.178
Body mass index
Body mass index(kg/m^2)C21 100 mg BID, SAS
Mean24.57 ± 4.119

12 further baseline measures are reported on the registry.

08

Study locations

21 sites
  • AMCMET Medical College and Sheth LG General Hospital
    Ahmedabad, Gujarat 380008, India
  • Unity Hospital
    Surat, Gujarat 395010, India
  • The Bhatia Hospital
    Mumbai, Maharashtra 400007, India
  • Grant Government Medical Collage and Sir J.J. Group of Hospitals
    Mumbai, Maharashtra 400008, India
  • N. K. P. Salve Institute of Medical Sciences & Research Centre and Lata Mangeshkar Hospital
    Nagpur, Maharashtra 440019, India
  • Ace Hospital & Research Center
    Pune, Maharashtra 411004, India
  • Oyster & Pearl Hospitals
    Pune, Maharashtra 411005, India
  • Hindusthan Hospital
    Coimbatore, Tamilnadu 641028, India
  • Jawaharlal Nehru Medical College - Aligarh Muslim University
    Alīgarh, Uttar Pradesh 202002, India
  • Midland Healthcare and Research Centre
    Lucknow, Uttar Pradesh, India
  • Apollo Spectra Hospitals (Apollo Speciality Hospital Pvt. Ltd.)
    Kanpur, 208001, India
  • Clinical Hospital for Emergency Medical Care n.a. N.V. Solovyev
    Yaroslavl, Russian Federation
  • MNCE City Clinical Hospital
    Kharkiv, 61124, Ukraine
  • Lviv National Medical University
    Lviv, 79010, Ukraine
  • Odessa Regional Hospital
    Odessa, 65025, Ukraine
  • Private Small Scale Enterprise Medical Center 'PULSE'
    Vinnytsia, 21001, Ukraine
  • University Hospital Birmingham
    Birmingham, B15 2TH, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
  • University College Hospital
    London, United Kingdom
  • University College London Hospitals
    London, United Kingdom
  • Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Mar 2024, 40 months.

Results were first posted in May 2025, 1 year 1 month after primary completion.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 40 months is above that.

Counting every sponsor, half of 76 studies reached it within 29 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2020
First posted
Aug 31, 2020
StartActual
Nov 13, 2020
Primary completionActual
Mar 30, 2024
CompletionActual
Mar 30, 2024
Results first posted
May 23, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04533022
Lead sponsor
Vicore Pharma AB
Collaborators
Orphan Reach Ltd.
Responsible party
Sponsor
First posted
Aug 31, 2020
Start date
Nov 13, 2020
Primary completion
Mar 30, 2024
Completion
Mar 30, 2024
Results posted
May 23, 2025
Last update
May 23, 2025

Study contacts

Joanna Porter, MD
principal investigator · Respiratory Medicine, University College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Compound 21

Start the discussion